Omalizumab response in patients with asthma by number and type of allergen
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Omalizumab response in patients with asthma by number and type of allergen
Authors
Keywords
-
Journal
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-04-08
DOI
10.1016/j.anai.2021.04.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018
- (2019) Karen M. MacDonald et al. Expert Review of Clinical Immunology
- Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma
- (2019) Jonathan Corren et al. Journal of Allergy and Clinical Immunology-In Practice
- Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
- (2018) Thomas B. Casale et al. Journal of Allergy and Clinical Immunology-In Practice
- Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease
- (2018) Merin E. Kuruvilla et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study
- (2017) Christian Domingo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells
- (2017) Regina Selb et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- IgE binds asymmetrically to its B cell receptor CD23
- (2017) Balvinder Dhaliwal et al. Scientific Reports
- Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma
- (2016) Trung N. Tran et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Asthma phenotypes and IgE responses
- (2015) Antoine Froidure et al. EUROPEAN RESPIRATORY JOURNAL
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Allergic Asthma Phenotype
- (2014) Michael Schatz et al. Journal of Allergy and Clinical Immunology-In Practice
- Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
- (2011) William W. Busse et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of environmental allergen sensitization on asthma morbidity in inner-city asthmatic children
- (2009) J. Wang et al. CLINICAL AND EXPERIMENTAL ALLERGY
- The development of allergic inflammation
- (2008) Stephen J. Galli et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More